WVE

Wave Life Sciences Ltd. [WVE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

WVE Stock Summary

Top 10 Correlated Stocks

WVE


In the News

08:30 29 Nov 2023 WVE

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET.

12:04 29 Nov 2023 WVE

Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call.

07:31 29 Nov 2023 WVE

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

08:30 29 Nov 2023 WVE

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023. Dr. Bolno will participate in the ADAR Editing Panel at 9:30 a.m. ET and an analyst-led fireside chat at 10:30 a.m. ET.

09:37 29 Nov 2023 WVE

2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss

Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.

05:09 29 Nov 2023 WVE

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK and Takeda, with the GSK deal potentially worth up to $3.3 billion in milestone payments.

08:30 29 Nov 2023 WVE

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available to view beginning on Monday, September 11, 2023, at 7:00 a.m. ET.

10:13 29 Nov 2023 WVE

WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months

WAVE Life Sciences Ltd. ( WVE , Financial), a preclinical biopharmaceutical company, has seen a significant increase in its stock price over the past three months.

03:14 29 Nov 2023 WVE

Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call.

10:31 29 Nov 2023 WVE

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.62 per share a year ago.

WVE Financial details

Company Rating
Neutral
Market Cap
525.98M
Income
-82.09M
Revenue
85.49M
Book val./share
-0.38
Cash/share
1.32
Dividend
-
Dividend %
-
Employees
250
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-6.61
Forward P/E
-4.79
PEG
1.03
P/S
5.93
P/B
-13.41
P/C
3.88
P/FCF
-24.63
Quick Ratio
1.47
Current Ratio
1.59
Debt / Equity
-0.83
LT Debt / Equity
-0.67
-
-
EPS (TTM)
-0.84
EPS next Y
-1.07
EPS next Q
-0.28
EPS this Y
-13.14%
EPS next Y
27.14%
EPS next 5Y
37.6%
EPS last 5Y
-16.53%
Revenue last 5Y
-24.02%
Revenue Q/Q
122.63%
EPS Q/Q
-134.2%
-
-
-
-
SMA20
-2.56%
SMA50
7.46%
SMA100
41.38%
Inst Own
50.31%
Inst Trans
0.71%
ROA
-41%
ROE
191%
ROC
-0.93%
Gross Margin
100%
Oper. Margin
-109%
Profit Margin
-96%
Payout
-
Shs Outstand
99.05M
Shs Float
44.65M
-
-
-
-
Target Price
-
52W Range
3.15-7.12
52W High
-26.86%
52W Low
+70.67%
RSI
42.59
Rel Volume
0.72
Avg Volume
292.61K
Volume
211.96K
Perf Week
-6.74%
Perf Month
-8.41%
Perf Quarter
23.97%
Perf Half Y
34.74%
-
-
-
-
Beta
-1.086
-
-
Volatility
0.12%, 0.18%
Prev Close
-2.1%
Price
5.12
Change
-3.21%

WVE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.50.470.510.790.05
Net income per share
-5.06-5.3-3.82-2.36-2.05
Operating cash flow per share
-0.79-5.56-2.96-1.72-1.62
Free cash flow per share
-1.13-5.67-2.99-1.73-1.64
Cash per share
6.034.354.72.911.12
Book value per share
2.531.882.110.63-0.57
Tangible book value per share
2.531.882.110.63-0.57
Share holders equity per share
2.531.882.110.63-0.57
Interest debt per share
0.360.960.750.580.46
Market cap
1.22B271.61M308.72M162.73M551.99M
Enterprise value
1.05B157M153.53M42.08M501.11M
P/E ratio
-8.3-1.51-2.06-1.33-3.41
Price to sales ratio
84.516.9915.383.97151.27
POCF ratio
-53.27-1.44-2.66-1.83-4.32
PFCF ratio
-37.13-1.41-2.63-1.82-4.27
P/B Ratio
16.64.263.735.01-12.24
PTB ratio
16.64.263.735.01-12.24
EV to sales
73.099.827.651.03137.33
Enterprise value over EBITDA
-6.7-0.74-1-0.33-3.08
EV to operating cash flow
-46.08-0.83-1.32-0.47-3.92
EV to free cash flow
-32.12-0.82-1.31-0.47-3.88
Earnings yield
-0.12-0.66-0.49-0.75-0.29
Free cash flow yield
-0.03-0.71-0.38-0.55-0.23
Debt to equity
0.140.510.350.92-0.83
Debt to assets
0.040.110.10.140.26
Net debt to EBITDA
1.050.541.010.950.31
Current ratio
1.561.571.92.531.38
Interest coverage
-7.25K09.59K0103.12
Income quality
0.160.970.770.730.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.743.062.121.1313.84
Research and developement to revenue
9.3310.986.522.9831.75
Intangibles to total assets
00000
Capex to operating cash flow
0.430.020.010.010.01
Capex to revenue
-0.69-0.25-0.07-0.01-0.37
Capex to depreciation
-1.78-0.43-0.13-0.06-0.13
Stock based compensation to revenue
1.081.220.710.44.71
Graham number
16.9814.9813.475.775.14
ROIC
-1.7-1.5-1.08-1.37-5.42
Return on tangible assets
-0.5-0.63-0.54-0.59-1.11
Graham Net
-1.39-1.580.4-0.46-1.31
Working capital
72.23M67.32M109M98.36M27.02M
Tangible asset value
73.35M63.73M82.78M32.5M-45.09M
Net current asset value
-20.32M-35.04M33.58M-11.95M-92.94M
Invested capital
0.140.510.350.92-0.83
Average receivables
5.5M15M25M15M0
Average payables
10.34M11.08M11.43M10.54M12.1M
Average inventory
04.81M10.03M5.22M0
Days sales outstanding
253.23456.74545.400
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.440.80.6700
Payables turnover
00000
Inventory turnover
00000
ROE
-2-2.82-1.81-3.763.59
Capex per share
-0.34-0.12-0.03-0.01-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.130.210.46
Net income per share
-0.42-0.47-0.24-0.20.07
Operating cash flow per share
-0.27-0.360.84-0.35-0.32
Free cash flow per share
-0.28-0.360.83-0.35-0.33
Cash per share
1.30.942.031.641.32
Book value per share
-0.05-0.48-0.34-0.49-0.38
Tangible book value per share
-0.05-0.48-0.34-0.49-0.38
Share holders equity per share
-0.05-0.48-0.34-0.49-0.38
Interest debt per share
0.410.380.330.330.32
Market cap
338.98M657.96M441.91M383.88M609.64M
Enterprise value
280.62M607.07M270.96M246.07M503.37M
P/E ratio
-2.17-3.76-4.5-4.5521.02
Price to sales ratio
1.19K531.0434.1817.3712.39
POCF ratio
-13.22-19.685.17-10.3-17.69
PFCF ratio
-12.99-19.565.2-10.28-17.59
P/B Ratio
-75.01-14.59-12.73-7.42-15.06
PTB ratio
-75.01-14.59-12.73-7.42-15.06
EV to sales
984.64489.9720.9611.1310.23
Enterprise value over EBITDA
-7.61-13.94-9.12-9.57113.27
EV to operating cash flow
-10.94-18.153.17-6.6-14.61
EV to free cash flow
-10.75-18.043.19-6.59-14.53
Earnings yield
-0.12-0.07-0.06-0.050.01
Free cash flow yield
-0.08-0.050.19-0.1-0.06
Debt to equity
-8.54-0.83-1.05-0.68-0.83
Debt to assets
0.210.260.140.150.17
Net debt to EBITDA
1.581.175.755.36-23.91
Current ratio
2.051.381.661.321.59
Interest coverage
-370.4725.8810.5200
Income quality
0.660.77-3.121.77-4.75
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
40.7311.080.950.550.27
Research and developement to revenue
96.7525.082.41.510.64
Intangibles to total assets
00000
Capex to operating cash flow
0.020.01-0.0100.01
Capex to revenue
-1.6-0.16-0.0400
Capex to depreciation
-0.18-0.08-0.2-0.03-0.09
Stock based compensation to revenue
11.812.350.210.110.05
Graham number
0.672.241.361.490.77
ROIC
-0.54-1.47-0.7-0.990.15
Return on tangible assets
-0.22-0.3-0.09-0.090.04
Graham Net
-0.68-1.1-0.93-1.03-0.86
Working capital
67.18M27.02M87.03M44.48M58.59M
Tangible asset value
-4.52M-45.09M-34.71M-51.72M-40.49M
Net current asset value
-54.6M-92.94M-82.39M-97M-81.83M
Invested capital
-8.54-0.83-1.05-0.68-0.83
Average receivables
00003.5M
Average payables
13.55M16.42M14.41M12.14M12.49M
Average inventory
00003.76M
Days sales outstanding
000012.8
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00007.03
Payables turnover
00000
Inventory turnover
00000
ROE
8.650.970.710.41-0.18
Capex per share
00000

WVE Frequently Asked Questions

What is Wave Life Sciences Ltd. stock symbol ?

Wave Life Sciences Ltd. is a SG stock and trading under the symbol WVE

What is Wave Life Sciences Ltd. stock quote today ?

Wave Life Sciences Ltd. stock price is $5.12 today.

Is Wave Life Sciences Ltd. stock public?

Yes, Wave Life Sciences Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap